Judah Frommer
Stock Analyst at Morgan Stanley
(2.73)
# 941
Out of 4,829 analysts
184
Total ratings
63.64%
Success rate
15.2%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $20.18 | +113.08% | 2 | May 9, 2025 | |
| BPMC Blueprint Medicines | Assumes: Equal-Weight | $120 → $100 | $100.27 | -0.27% | 1 | Mar 20, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $6.40 | +87.50% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $7.97 | +201.13% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $25.07 | -12.25% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $3.32 | +80.72% | 2 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $17.52 | +76.94% | 1 | Nov 21, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $59.50 | +78.15% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $14.19 | +146.65% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.64 | +392.42% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $0.75 | +300.00% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $4.74 | +743.88% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.05 | +1,138.10% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $29.33 | +2.28% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $9.66 | +138.10% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $46.01 | +8.67% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $36.37 | +287.68% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.15 | +1,030.43% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.44 | +525.00% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $19.22 | +14.46% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.01 | +39.72% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $5.68 | +40.85% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $11.71 | +292.83% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $0.80 | +776.20% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $13.15 | +318.25% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $67.75 | -32.10% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $87.52 | -44.01% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $1,016.15 | -63.59% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $73.54 | -57.85% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $71.93 | +5.66% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $89.49 | +103.37% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $89.00 | +20.22% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $113.91 | -16.60% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $22.30 | -19.28% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $103.49 | +12.09% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $111.71 | -65.98% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $156.99 | -85.99% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $69.04 | -49.30% | 9 | Apr 29, 2020 |
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $20.18
Upside: +113.08%
Blueprint Medicines
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $120 → $100
Current: $100.27
Upside: -0.27%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $6.40
Upside: +87.50%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $7.97
Upside: +201.13%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $25.07
Upside: -12.25%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $3.32
Upside: +80.72%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $17.52
Upside: +76.94%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $59.50
Upside: +78.15%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $14.19
Upside: +146.65%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.64
Upside: +392.42%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $0.75
Upside: +300.00%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $4.74
Upside: +743.88%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.05
Upside: +1,138.10%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $29.33
Upside: +2.28%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $9.66
Upside: +138.10%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $46.01
Upside: +8.67%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $36.37
Upside: +287.68%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.15
Upside: +1,030.43%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.44
Upside: +525.00%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $19.22
Upside: +14.46%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.01
Upside: +39.72%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $5.68
Upside: +40.85%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $11.71
Upside: +292.83%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $0.80
Upside: +776.20%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $13.15
Upside: +318.25%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $67.75
Upside: -32.10%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $87.52
Upside: -44.01%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $1,016.15
Upside: -63.59%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $73.54
Upside: -57.85%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $71.93
Upside: +5.66%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $89.49
Upside: +103.37%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $89.00
Upside: +20.22%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $113.91
Upside: -16.60%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $22.30
Upside: -19.28%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $103.49
Upside: +12.09%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $111.71
Upside: -65.98%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $156.99
Upside: -85.99%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $69.04
Upside: -49.30%